Drug Profile


Alternative Names: CS-3150; XL-550

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Exelixis
  • Developer Daiichi Sankyo Company
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension; Hyperaldosteronism; Hypertension
  • Phase II Diabetic nephropathies
  • No development reported Cardiovascular disorders; Heart failure

Most Recent Events

  • 23 Mar 2017 Daiichi Sankyo completes a phase I drug-drug interaction trial in Healthy volunteers in Japan (PO) (JapicCTI-163379)
  • 01 Mar 2017 Daiichi Sankyo completes a phase III trial in Hypertension (in patients with type-2 diabetes mellitus and albuminuria) in Japan (NCT02807974)
  • 01 Feb 2017 Daiichi Sankyo completes a phase III trial in Hypertension in Japan (PO) (NCT02808026; JapicCTI-163287)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top